https://ntp.niehs.nih.gov/go/14830

Target Organs and Levels of Evidence for TR-491

Toxicology and Carcinogenesis Studies of Methyleugenol (CASRN 93-15-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies)

Chemical (Study Title)
CASRN		 Peer Review Date Route/Exposure Levels Study Laboratory
Methyleugenol
93-15-2		   Gavage
0,10,30,100,300,1000 MG/KG PLUS SHAM GAVAGE GROUP		 Southern Research Institute

Levels of Evidence: None

 
Chemical (Study Title)
CASRN		 Peer Review Date Route/Exposure Levels Study Laboratory
Methyleugenol
93-15-2		 10/30/1998 Gavage
R&M: 0, 37, 75, OR 150 MG/KG; 50/SEX/SPECIES/GROUP		 Battelle Columbus Laboratory

Levels of Evidence

Male Rats: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 5/50 12/50 23/50 38/50 32/50 OR CARCINOMA 2/50 3/50 14/50 25/50 36/50 COMBINED 7/50 14/50 28/50 43/50 45/50; HEPATOCHOLANGIOMA 0/50 0/50 0/50 1/50 6/50 OR HEPATOCHOLANGIOCARCINOMA 0/50 0/50 1/50 1/50 7/50 COMBINED 0/50 0/50 1/50 2/50 13/50
  • Glandular Stomach: BENIGN NEUROENDOCRINE TUMOR 1/50 0/50 0/50 3/50 2/50 OR MALIGNANT NEURENDOCRINE TUMOR 0/50 0/50 0/50 4/50 2/50 COMBINED 1/50 0/50 0/50 7/50 4/50
  • Kidney Tubular Cell: ADENOMA (STANDARD AND EXTENDED COMBINED) 4/50 6/50 17/50 13/50 20/50
  • Mesothelium (Abdominal Cavity/Tunica Vaginalis): MESOTHELIOMA 1/50 3/50 5/50 12/50 5/50
  • Mammary Gland: FIBROADENOMA 5/50 5/50 15/50 13/50 6/50
  • Skin: FIBROMA 1/50 9/50 8/50 5/50 4/50 OR FIBROMA OR FIBROSARCOMA 1/50 12/50 8/50 8/50 4/50
Non-Neoplastic Lesions
  • LIVER: EOSINOPHILIC FOCI, MIXED CELL FOCI; HEPATOCYTE HYPERTROPHY; OVAL CELL HYPERPLASIA; CYSTIC DEGENERATION
  • GLANDULAR STOMACH: NEUROENDOCRINE CELL HYPERPLASIA; ATROPHY
Female Rats: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 1/50 8/50 11/49 33/49 43/50 OR CARCINOMA 0/50 0/50 4/49 8/49 22/50 COMBINED 1/50 8/50 14/49 34/49 43/50; HEPATOCHOLANGIOMA 0/50 0/50 0/49 0/49 8/50 OR HEPATOCHOLANGIOCARCINOMA 0/50 0/50 0/49 3/49 9/50 COMBINED 0/50 0/50 0/49 3/49 17/50
  • Glandular Stomach: BENIGN NEUROENDOCRINE TUMOR 0/50 0/50 13/50 9/50 5/50 OR MALIGNANT NEUROENDOCRINE TUMOR 0/50 1/50 12/50 26/50 36/50 COMBINED 0/50 1/50 25/50 34/50 41/50
May Have Been Related
  • Forestomach: SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 1/50 3/50
Non-Neoplastic Lesions
  • LIVER: EOSINOPHILIC FOCI, MIXED CELL FOCI; HEPATOCYTE HYPERTROPHY; OVAL CELL HYPERPLASIA, BILE DUCT HYPERPLASIA; CYSTIC DEGENERATION
  • GLANDULAR STOMACH: NEUROENDOCRINE CELL HYPERPLASIA; ATROPHY
Male Mice: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 26/49 43/50 38/50 39/50 CARCINOMA 10/49 20/50 19/50 9/50 COMBINED 31/49 47/50 46/50 40/50; HEPATOBLASTOMA 0/49 0/50 1/50 3/50
  • Glandular Stomach: MALIGNANT NEUROENDOCRINE TUMOR 0/49 0/48 0/49 2/50
Non-Neoplastic Lesions
  • LIVER: EOSINOPHILIC FOCI; OVAL CELL HYPERPLASIA; HEPATOCYTE HYPERTROPHY
  • GLANDULAR STOMACH: ATROPHY; HYPERPLASIA; ECTASIA
Female Mice: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 20/50 48/50 46/49 41/50 OR CARCINOMA 7/50 37/50 47/49 47/50 COMBINED 25/50 50/50 49/49 49/50; HEPATOBLASTOMA 0/50 6/50 11/49 15/50; HEPATOCHOLANGIOCARCINOMA 0/50 0/50 0/50 2/50
Non-Neoplastic Lesions
  • LIVER: OVAL CELL HYPERPLASIA; HEPATOCYTE HYPERTROPHY; HEPATOCYTE NECROSIS; HEMATOPOIETIC CELL PROLIFERATION; BILE DUCT HYPERPLASIA; HEMOSIDERIN PIGMENTATION
  • GRANDULAR STOMACH: ATROPHY; ECTASIA